Crofelemer

Crofelemer
Clinical data
Trade namesMytesi
Other namesSP-303
AHFS/Drugs.comMonograph
MedlinePlusa613016
License data
Routes of
administration		By mouth (oral tablets)
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityLittle or no absorption from the gut
Identifiers
CAS Number
PubChem SID
DrugBank
ChemSpider
  • none
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
Formula(C15O6,7H12)n
Molar mass860–9100 g·mol−1

Crofelemer (USAN, trade name Mytesi) is an antidiarrheal indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.[1] Other possible uses include diarrhea in children, acute infectious diarrhea, and diarrhea in patients with irritable bowel syndrome.[2] It is a purified oligomeric proanthocyanidin from "dragon's blood", the sap of the South American tree Croton lechleri.[3]

Crofelemer treats the symptoms of disease, but it is not used to treat infectious diarrhea (diarrhea caused by infection of the digestive system by a bacterium, virus or parasite). It was initially developed by Napo Pharmaceuticals, which is a wholly owned subsidiary of Jaguar Health, Inc. A Phase III clinical trial for diarrhea in HIV patients was completed in 2012, and the drug was approved by the US Food and Drug Administration (FDA) on 31 December 2012.[4][5][6]

  1. ^ "Mytesi Full Prescribing Information".
  2. ^ Cite error: The named reference Drugs.com was invoked but never defined (see the help page).
  3. ^ Cite error: The named reference Tradtrantip was invoked but never defined (see the help page).
  4. ^ Cite error: The named reference Spreitzer was invoked but never defined (see the help page).
  5. ^ Cite error: The named reference ADVENT was invoked but never defined (see the help page).
  6. ^ Cite error: The named reference FDA was invoked but never defined (see the help page).